EAGLE PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.16 USD | -1.89% |
|
-9.76% | -20.46% |
| Apr. 22 | North American Morning Briefing : Stock Futures -2- | DJ |
| Apr. 15 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 797.1 | 600.9 | 821.4 | 606.8 | 657.6 | 380.5 |
| Enterprise Value (EV) 1 | 730.2 | 566.5 | 754.2 | 541.9 | 589.7 | 390.6 |
| P/E ratio | 16.3 x | 19.3 x | 59.5 x | 53.5 x | -77 x | 10.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 3.37 x | 2.82 x | 4.19 x | 3.23 x | 3.83 x | 1.2 x |
| EV / Revenue | 3.08 x | 2.66 x | 3.85 x | 2.89 x | 3.44 x | 1.23 x |
| EV / EBITDA | 9.21 x | 11.3 x | 29.8 x | 14.8 x | 90.3 x | 3.47 x |
| EV / FCF | 16.4 x | 18.7 x | 14.2 x | 10.8 x | 18.6 x | 4.46 x |
| FCF Yield | 6.08% | 5.35% | 7.02% | 9.24% | 5.37% | 22.4% |
| Price to Book | 4.43 x | 3.49 x | 4.57 x | 3.27 x | 3.69 x | 1.63 x |
| Nbr of stocks (in thousands) | 14,922 | 14,913 | 13,671 | 13,030 | 12,914 | 13,016 |
| Reference price 2 | 53.42 | 40.29 | 60.08 | 46.57 | 50.92 | 29.23 |
| Announcement Date | 2/26/18 | 2/28/19 | 3/2/20 | 3/5/21 | 3/8/22 | 3/23/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 236.7 | 213.3 | 195.9 | 187.8 | 171.5 | 316.6 |
| EBITDA 1 | 79.24 | 50.14 | 25.31 | 36.49 | 6.529 | 112.5 |
| EBIT 1 | 75.5 | 46.47 | 21.82 | 32.95 | 2.769 | 100.5 |
| Operating Margin | 31.9% | 21.78% | 11.14% | 17.55% | 1.61% | 31.73% |
| Earnings before Tax (EBT) 1 | 72.94 | 34.04 | 22 | 22.68 | -4.548 | 61.43 |
| Net income 1 | 51.94 | 31.9 | 14.31 | 11.99 | -8.627 | 35.64 |
| Net margin | 21.94% | 14.96% | 7.31% | 6.38% | -5.03% | 11.26% |
| EPS 2 | 3.270 | 2.090 | 1.010 | 0.8700 | -0.6610 | 2.730 |
| Free Cash Flow 1 | 44.4 | 30.32 | 52.97 | 50.08 | 31.68 | 87.63 |
| FCF margin | 18.76% | 14.22% | 27.04% | 26.67% | 18.47% | 27.68% |
| FCF Conversion (EBITDA) | 56.03% | 60.48% | 209.32% | 137.24% | 485.22% | 77.9% |
| FCF Conversion (Net income) | 85.48% | 95.05% | 370.1% | 417.74% | - | 245.85% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/26/18 | 2/28/19 | 3/2/20 | 3/5/21 | 3/8/22 | 3/23/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 41.25 | 48.12 | 39.85 | 42.32 | 115.9 | 74.14 | 65.9 | 60.7 | 66.3 | 64.65 |
| EBITDA 1 | 4.111 | 11.74 | 9.81 | 13.46 | - | 25.93 | 19.33 | 19.98 | 22.32 | 20.68 |
| EBIT 1 | 4.111 | 10.85 | 8.907 | 5.899 | 61.67 | 24.29 | 18.94 | 19.83 | 16.77 | 14.7 |
| Operating Margin | 9.97% | 22.54% | 22.35% | 13.94% | 53.22% | 32.77% | 28.73% | 32.67% | 25.3% | 22.73% |
| Earnings before Tax (EBT) 1 | 1.34 | 5.548 | -12.66 | 1.224 | - | -5.868 | -0.045 | 13.3 | 10.23 | 9.298 |
| Net income 1 | -0.421 | 3.612 | -5.622 | -6.196 | 44.06 | -9.45 | -3.513 | 8.165 | 5.75 | 5.164 |
| Net margin | -1.02% | 7.51% | -14.11% | -14.64% | 38.02% | -12.75% | -5.33% | 13.45% | 8.67% | 7.99% |
| EPS 2 | -0.0300 | 0.2700 | -0.4300 | -0.4800 | 3.410 | -0.7400 | -0.2700 | 0.6200 | 0.4400 | 0.3900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/10/21 | 8/9/21 | 11/9/21 | 3/7/22 | 5/9/22 | 8/9/22 | 11/7/22 | 3/13/23 | 5/9/23 | 8/8/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 10.2 |
| Net Cash position 1 | 66.9 | 34.4 | 67.1 | 64.9 | 67.8 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | 0.0906 x |
| Free Cash Flow 1 | 44.4 | 30.3 | 53 | 50.1 | 31.7 | 87.6 |
| ROE (net income / shareholders' equity) | 31.4% | 18.8% | 8.42% | 6.57% | -4.76% | 17.4% |
| ROA (Net income/ Total Assets) | 19.5% | 11.4% | 5.53% | 8.11% | 0.68% | 19% |
| Assets 1 | 266.6 | 279.4 | 258.9 | 147.8 | -1,264 | 187.3 |
| Book Value Per Share 2 | 12.10 | 11.60 | 13.10 | 14.20 | 13.80 | 17.90 |
| Cash Flow per Share 2 | 7.720 | 5.660 | 8.050 | 7.900 | 7.630 | 4.250 |
| Capex 1 | 4.44 | 0.13 | 0.78 | 0.75 | 0.32 | 0.18 |
| Capex / Sales | 1.87% | 0.06% | 0.4% | 0.4% | 0.19% | 0.06% |
| Announcement Date | 2/26/18 | 2/28/19 | 3/2/20 | 3/5/21 | 3/8/22 | 3/23/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -20.46% | 54.03M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- EGRX Stock
- Financials Eagle Pharmaceuticals, Inc.
